AMCP’s Post

JUST IN: Early data from an ongoing clinical trial suggests that injectable asthma medication, Xolair, may mitigate food-related allergic reactions in children. Promising results could lead to FDA approval as a treatment for food allergies. #Xolair #ASTHMA #FoodAllergies #TheReportify. Share your thoughts in the comments! To learn more and read the complete story, click on this link. https://lnkd.in/g9Cw7jj4

A New (actually old) and Effectjve Therapy for Childhood Allergies 2/27/24 An old asthma drug, Xolair, which is a monoclonal antibody that binds and neutralizes IgE - a central molecule in allergic reactions - has been repurposed as a food allergy drug in this RCT just published in the NEJM. This could signal a huge breath of relief for parents of children with multiple allergies - though it is costly and requires repeated administration. Despite society-wide efforts to bring attention to this matter (eg. every restaurant must ask its patrons if any food allergies exist), too many epi-pens are needed Each year in the U.S., it is estimated that anaphylaxis to food results in 30,000 emergency room visits, 2,000 hospitalizations, and 150 deaths. The perennial angst (and fear) of parents of children with serious food allergies at risk of anaphylactic shock is one metric that goes unaccounted. And it happens in adults too https://lnkd.in/ejfcKk3N Hopefully, the marked benefit seen in this placebo-controlled trial will foster new research to develop better agents that are oral (not injected). #peanutallergy #allergens #childhoodallergies #xolair

7 common causes of pediatric GI bleeding Parenting is a journey during which you encounter things you weren't prepared for, especially when your child is sick. One of the scariest situations for parents is when a child has blood in their stool or vomit, which is known as gastrointestinal (GI) bleeding. 1. Constipation 2. Ulcers 3. Meckel’s diverticulum 4. Food allergies 5. Gastritis 6. Inflammatory bowel disease 7. Polyps

Test your knowledge of food allergies with this clinical challenge! Enhance your understanding of this topic by exploring the link provided. #FoodAllergies #ClinicalChallenges

Interesting topic - I learned a lot from these folks in a session a couple of weeks ago. Try to join if you can! Payer Insights and Perspectives from AMCP Market Insights As new therapeutic options emerge for managing food allergies, managed care organizations face the crucial task of evaluating their clinical efficacy and safety profiles to formulate coverage policies. Considering the potential for new therapeutics to reduce emergency room visits and enhance patients' quality of life, it is essential to assess the cost implications comprehensively. On March 27, join us for this webinar as we delve into these critical considerations and explore strategies to accommodate innovative treatments in managed care.

We are revisiting a 20-year-old Asthma drug which significantly reduces risk of fatal food allergies. According to a recent report in The Times, ground-breaking research from the Johns Hopkins Children's Centre in Baltimore, recently published in the New England Journal of Medicine (NEJM), has revealed that a two-decade-old asthma medication, Xolair, can significantly mitigate severe allergic reactions to a range of foods, such as peanuts, cashews, wheat, milk, and eggs. This pioneering treatment is the first of its kind to offer protection against multiple life-threatening food allergies, heralding a transformative breakthrough that could dramatically improve the lives of thousands of children and adults. Xolair, also known by its generic name omalizumab, is a revolutionary monoclonal antibody that has been a game-changer in the field of allergy treatment, particularly for individuals who suffer from severe allergies. This commentary provides an educational overview of the life-saving benefits of Xolair. Read my full commentary and TImes article following the link: https://lnkd.in/gx5XxfTZ

🌟𝗘𝘅𝗰𝗶𝘁𝗶𝗻𝗴 𝗣𝗿𝗼𝗴𝗿𝗲𝘀𝘀 𝗶𝗻 𝗙𝗼𝗼𝗱 𝗔𝗹𝗹𝗲𝗿𝗴𝘆 𝗧𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁 𝘄𝗶𝘁𝗵 𝗢𝗺𝗮𝗹𝗶𝘇𝘂𝗺𝗮𝗯🌟   Groundbreaking research, led by Dr. Robert A. Wood from The Johns Hopkins University in #Baltimore and esteemed colleagues, unveils the potential of omalizumab in managing multiple food allergies. 🥜🥚🥛   In a recent clinical trial involving 180 participants grappling with peanut and other food allergies, omalizumab demonstrated significant efficacy compared to a placebo.   👉 67% of omalizumab recipients displayed increased tolerance to a single dose of 600 mg of peanut protein, compared to just 7% in the placebo group. This finding marks a substantial advancement in food allergy management! Beyond peanuts, secondary analyses revealed notable improvements in tolerance levels to other common allergens such as cashew, milk, and egg. 💊   This study highlights the potential of omalizumab as a transformative therapeutic option for food allergies, offering hope to individuals across various age groups. 🔬🔝   See more: https://lnkd.in/d_y_xR_q   If you're ready to use licensed molecules in your research, contact us. We're here to meet your needs and help you source the clinical-grade molecules you require. Accelerate your R&D and discover the potential of aliquots in our online shop. (Link in the comments) 📊   #Evidentic #ClinicalGradeMolecules #ResearchAndDevelopment #DrugDevelopment #InnovationInMedicine #Antibody #mAb #ClinicalGrade #DrugDevelopment #DrugDiscovery #BetterHealth #Biotech #foodallergy🧪🌐

Many food allergens have been characterized at the molecular level, which has contributed to an increased understanding of the immunopathogenesis of many allergic disorders and might soon lead to novel diagnostic and immunotherapeutic approaches. The management of food allergies continues to consist of educating patients on how to avoid relevant allergens, recognizing early symptoms of an allergic reaction in case of accidental ingestion, and initiating the appropriate emergency therapy.  Visit our journal website for more updates: https://lnkd.in/dQ84mS8f (Source: Internet) Submissions are open for an upcoming issue! Submit your manuscript to immunologyallergy@maplesjournal.com #foodallergy #digestion #immunopathogenesis #therapy #allergicdisorders #ingestion #novelapproaches #immunesystem #emergency

New England Journal of Medicine Publishes Phase III Data Showing Xolair Significantly Reduced Allergic Reactions Across Multiple Foods in People With Food Allergies * Detailed results from the NIH-sponsored Phase III OUtMATCH study showed treatment with Xolair increased the amount of peanuts, tree nuts, egg, milk, and wheat that people as young as 1-year consumed without an allergic reaction. * The U.S. FDA recently approved Xolair as the first and only medicine for children and adults with one or more food allergies. * Allergic reactions can be life-threatening, and it is estimated that food-related anaphylaxis results in 30,000 medical events treated in emergency rooms in the U.S. each year. Read the full article and results from Genentech: https://buff.ly/49rNH7l Hear a short message from NIH/NIAID: https://buff.ly/3Td3XTT #AAAAI24 #FoodAllergy #FoodAllergies #Allergy #Anaphylaxis #Treatment #Research #Xolair #Omalizumab #OUtMATCH #FoodAllergyAwareness #AllergyAwareness #Peanut #PeanutAllergy #TreeNuts #Nuts #Egg #Milk #Wheat #FAACT #LearnTheFAACTs #KnowTheFAACTs #ShareTheFAACTs

Don't miss this new 2-part podcast series, created in collaboration with FARE, "IgE-Mediated Food Allergies- Therapeutic Innovations to the Rescue," with Dr. Kelly Cleary!   In Episode 2, "Advances in the Management of IgE-Mediated Food Allergies," Drs. Kelly Cleary and Robert Wood discuss the efficacy and safety of traditional and emerging treatments as well as evidence-based guidance for managing patients with immunoglobulin E (IgE)-mediated food allergies.   This activity is supported by an educational grant from Genentech, a member of the Roche Group.   Listen to this podcast series here: https://lnkd.in/e8rVix87   #foodallergies #foodallergyawareness